| Literature DB >> 27268286 |
Michaela Spitzer1, Nicole Robbins1, Gerard D Wright1.
Abstract
Invasive fungal infections are an important cause of human mortality and morbidity, particularly for immunocompromised populations. However, there remains a paucity of antifungal drug treatments available to combat these fungal pathogens. Further, antifungal compounds are plagued with problems such as host toxicity, fungistatic activity, and the emergence of drug resistance in pathogen populations. A promising therapeutic strategy to increase drug effectiveness and mitigate the emergence of drug resistance is through the use of combination drug therapy. In this review we describe the current arsenal of antifungals in medicine and elaborate on the benefits of combination therapy to expand our current antifungal drug repertoire. We examine those antifungal combinations that have shown potential against fungal pathogens and discuss strategies being employed to discover novel combination therapeutics, in particular combining antifungal agents with non-antifungal bioactive compounds. The findings summarized in this review highlight the promise of combinatorial strategies in combatting invasive mycoses.Entities:
Keywords: Aspergillus; Candida; Cryptococcus; antifungal; combination therapy; drug synergy
Mesh:
Substances:
Year: 2016 PMID: 27268286 PMCID: PMC5354157 DOI: 10.1080/21505594.2016.1196300
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882